What a serious longevity check-up should — and should not — promise
A buyer’s framework for separating clinically useful prevention from expensive theatre.
Start with the person, not the package
The strongest programmes begin with history, age, symptoms, family risk, medications and goals. A fixed panel sold identically to everyone is easy to market but weakly personalised.
A test needs an action path
Before adding a test, ask what a normal result changes, what an abnormal result changes, who interprets it and who follows up. If the answer is vague, the test may be more theatre than medicine.
Novel is not the same as useful
Biological-age scores, broad genetic panels and emerging biomarkers can be interesting. They become clinically meaningful only when the method is validated for the intended use and the result changes a decision.
Continuity is the premium
The best marker of quality may be what happens after the report: a clear plan, responsibilities, repeat intervals and referral when something is abnormal.
Sources & further reading
Interpretation matters: evidence applies to the population, intervention and outcome actually studied. We avoid converting population-level findings into individual promises.